Company profile for CUBIST PHARMS INC

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

It takes a world-class organization to deliver powerful medicines and solutions for some of the greatest medical challenges. Each of our teams is distinct and important, and they are an essential component of our combined success. At Cubist, we never lose sight of our commitment to patients. They are why we take on some of the greatest medical challenges of our time. For more than 20 years, we have not wavered from our com...
It takes a world-class organization to deliver powerful medicines and solutions for some of the greatest medical challenges. Each of our teams is distinct and important, and they are an essential component of our combined success. At Cubist, we never lose sight of our commitment to patients. They are why we take on some of the greatest medical challenges of our time. For more than 20 years, we have not wavered from our commitment to bringing medicines to patients with complex illnesses. Worldwide our therapies have treated approximately 2.5 million patients. We have a particular focus on saving lives and fighting superbugs. We know superbugs will continue to evolve but we can work to stay ahead of them, helping patients receive the right medicines they need if they are faced with serious illnesses caused by dangerous bacteria. We want patients up and out of hospitals and hospital settings faster. Every patient deserves to get better. We strive to make it possible.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Switzerland
Address
Address
Thurgauerstrasse 36/38, 8050 Zurich
Telephone
Telephone
+41 58 433 43 00
Client Website
Website
--
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Merck scores a new Zerbaxa indication
Merck scores a new Zerbaxa indication

05 Jun 2019

// Eric Sagonowsky FIERCE PHARMA

https://www.fiercepharma.com/pharma/merck-scores-zerbaxa-label-expansion-years-after-cubist-buyout

Eric Sagonowsky FIERCE PHARMA
05 Jun 2019
Merck set to seek EU, US approval of Zerbaxa for pneumonia
Merck set to seek EU, US approval of Zerbaxa for pneumonia

12 Sep 2018

// Matthew Dennis FIRST WORD PHARMA

https://www.firstwordpharma.com/node/1590308

Matthew Dennis FIRST WORD PHARMA
12 Sep 2018

https://endpts.com/merck-heralds-a-rare-big-pharma-success-for-antibiotic-phiii-but-its-also-a-cautionary-tale-about-the-market/

John Carroll ENDPTS
11 Sep 2018

http://www.biospace.com/News/kaleido-biosciences-emerges-from-stealth-mode-with/469546/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews

Mark Terry BIOSPACE
18 Sep 2017

http://www.fiercepharma.com/pharma/generics-set-to-undercut-blockbusters-from-merck-novartis-bms-2017

Eric Sagonowsky FIERCE PHARMA
18 Jan 2017

http://www.prnewswire.com/news-releases/amplyx-pharmaceuticals-appoints-ciara-kennedy-phd-as-president-and-chief-executive-officer-300384074.html

PR NEWSWIRE
05 Jan 2017

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty